Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immix Biopharma, Inc. - Common Stock (NQ: IMMX ) 2.410 +0.210 (+9.55%) Streaming Delayed Price Updated: 3:30 PM EDT, May 15, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 123,276 Open 2.270 Bid (Size) 2.370 (3) Ask (Size) 2.420 (1) Prev. Close 2.200 Today's Range 2.210 - 2.440 52wk Range 1.400 - 7.750 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News IMMX Stock Earnings: Immix Biopharma Beats EPS for Q1 2024 May 13, 2024 IMMX stock results show that Immix Biopharma beat analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma April 29, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Performance YTD -60.23% -60.23% 1 Month -9.40% -9.40% 3 Month -14.23% -14.23% 6 Month -45.23% -45.23% 1 Year +16.99% +16.99% More News Read More Immix Biopharma on Track to Dose NXC-201 Patients in United States April 18, 2024 From Immix Biopharma, Inc. Via GlobeNewswire IMMX Stock Earnings: Immix Biopharma Misses EPS for Q4 2023 April 02, 2024 Via InvestorPlace Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial March 20, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative March 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire BioMedNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering February 09, 2024 Via Investor Brand Network Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock February 08, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis February 07, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Proposed Public Offering of Common Stock February 05, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 25, 2024 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session January 25, 2024 Via Benzinga Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products January 24, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board January 04, 2024 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board December 18, 2023 From Immix Biopharma, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Friday's Intraday Session December 15, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Intraday Session December 14, 2023 Via Benzinga Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023 December 11, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Present at the 2023 JMP Securities Hematology and Oncology Summit November 30, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis November 22, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing November 21, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients November 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients November 06, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Immix Biopharma Subsidiary Nexcella Announces Dr. Michaela Liedtke, Stanford Medicine Cancer Center Hematology Program Lead and Co-Director Stanford Amyloid Center, Joins Scientific Advisory Board October 26, 2023 From Immix Biopharma, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
